BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31153787)

  • 1. Estimating liver function in a large cirrhotic cohort: Signal intensity of gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI.
    Ippolito D; Famularo S; Giani A; Orsini EB; Pecorelli A; Pinotti E; Gandola D; Romano F; Sironi S; Bernasconi DP; Gianotti L
    Dig Liver Dis; 2019 Oct; 51(10):1438-1445. PubMed ID: 31153787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatobiliary phase images using gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI as an imaging surrogate for the albumin-bilirubin grading system.
    Takatsu Y; Kobayashi S; Miyati T; Shiozaki T
    Eur J Radiol; 2016 Dec; 85(12):2206-2210. PubMed ID: 27842668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing liver function: diagnostic efficacy of parenchymal enhancement and liver volume ratio of Gd-EOB-DTPA-enhanced MRI study during interstitial and hepatobiliary phase.
    Ippolito D; Pecorelli A; Famularo S; Bernasconi D; Orsini EB; Giani A; Romano F; Talei Franzesi C; Sironi S
    Abdom Radiol (NY); 2019 Apr; 44(4):1340-1349. PubMed ID: 30411177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral.
    Li XH; Huang R; Yang M; Wang J; Gao YH; Jin Q; Ma DL; Wei L; Rao HY
    World J Gastroenterol; 2022 May; 28(20):2214-2226. PubMed ID: 35721884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic-contrast-enhanced magnetic resonance imaging of cirrhotic liver parenchyma: A comparison between gadolinium-diethylenetriamine pentaacetic acid and gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid.
    Lin CY; Chang WC; Chou CT; Chen RC
    J Chin Med Assoc; 2015 Nov; 78(11):666-72. PubMed ID: 26341453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of liver function using liver parenchyma, spleen and portal vein signal intensities during the hepatobiliary phase in Gd-EOB-D TPA-enhanced MRI.
    Yang M; Zhang Y; Zhao W; Cheng W; Wang H; Guo S
    BMC Med Imaging; 2020 Oct; 20(1):119. PubMed ID: 33081713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver function correlates with liver-to-portal vein contrast ratio during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MR at 3 Tesla.
    Zhang W; Wang X; Miao Y; Hu C; Zhao W
    Abdom Radiol (NY); 2018 Sep; 43(9):2262-2269. PubMed ID: 29476347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical factors predictive of insufficient liver enhancement on the hepatocyte-phase of Gd-EOB-DTPA-enhanced magnetic resonance imaging in patients with liver cirrhosis.
    Kim HY; Choi JY; Park CH; Song MJ; Song DS; Kim CW; Bae SH; Yoon SK; Lee YJ; Rha SE
    J Gastroenterol; 2013 Oct; 48(10):1180-7. PubMed ID: 23354621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic uptake index in the hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine penta acetic acid-enhanced magnetic resonance imaging estimates functional liver reserve and predicts post-hepatectomy liver failure.
    Donadon M; Lanza E; Branciforte B; Muglia R; Lisi C; Pedicini V; Poretti D; Famularo S; Balzarini L; Torzilli G
    Surgery; 2020 Sep; 168(3):419-425. PubMed ID: 32600880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a predictor of insufficient enhancement during the hepatobiliary phase of Gd-EOB-DTPA-enhanced magnetic resonance imaging.
    Cui E; Long W; Luo L; Hu M; Huang L; Chen X
    Acta Radiol; 2017 Oct; 58(10):1174-1181. PubMed ID: 28090793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic enhancement of Gd-EOB-DTPA-enhanced 3 Tesla MR imaging: Assessing severity of liver cirrhosis.
    Lee S; Choi D; Jeong WK
    J Magn Reson Imaging; 2016 Nov; 44(5):1339-1345. PubMed ID: 27197633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests.
    Kukuk GM; Schaefer SG; Fimmers R; Hadizadeh DR; Ezziddin S; Spengler U; Schild HH; Willinek WA
    Eur Radiol; 2014 Oct; 24(10):2482-90. PubMed ID: 25030459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring hepatic functional reserve using T1 mapping of Gd-EOB-DTPA enhanced 3T MR imaging: A preliminary study comparing with
    Nakagawa M; Namimoto T; Shimizu K; Morita K; Sakamoto F; Oda S; Nakaura T; Utsunomiya D; Shiraishi S; Yamashita Y
    Eur J Radiol; 2017 Jul; 92():116-123. PubMed ID: 28624009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging predicts the histological grade of hepatocellular carcinoma only in patients with Child-Pugh class A cirrhosis.
    Kim HY; Choi JY; Kim CW; Bae SH; Yoon SK; Lee YJ; Rha SE; You YK; Kim DG; Jung ES
    Liver Transpl; 2012 Jul; 18(7):850-7. PubMed ID: 22407909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy of the gadoxetic acid MRI-derived relative enhancement index (REI) and functional liver imaging score (FLIS) in predicting liver function: validation with Albumin-Bilirubin (ALBI) grade.
    Eryuruk U; Tasdemir MN; Karasu HI; Aslan S
    Abdom Radiol (NY); 2024 May; 49(5):1456-1466. PubMed ID: 38653813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of hepatobiliary phase delay time of Gd-EOB-DTPA-enhanced magnetic resonance imaging for identification of hepatocellular carcinoma in patients with cirrhosis of different degrees of severity.
    Wu JW; Yu YC; Qu XL; Zhang Y; Gao H
    World J Gastroenterol; 2018 Jan; 24(3):415-423. PubMed ID: 29391764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic parenchymal enhancement at Gd-EOB-DTPA-enhanced MR imaging: correlation with morphological grading of severity in cirrhosis and chronic hepatitis.
    Kanki A; Tamada T; Higaki A; Noda Y; Tanimoto D; Sato T; Higashi H; Ito K
    Magn Reson Imaging; 2012 Apr; 30(3):356-60. PubMed ID: 22227353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver function test by gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging with consideration of intrahepatic regional differences.
    Okubo H; Mogami M; Ozaki Y; Igusa Y; Aoyama T; Amano M; Kokubu S; Miyazaki A; Watanabe S
    Hepatogastroenterology; 2013 Oct; 60(127):1547-51. PubMed ID: 23933786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine.
    Khouri Chalouhi C; Vernuccio F; Rini F; Duca P; Tuscano B; Brancatelli G; Vanzulli A
    Eur Radiol; 2019 Jun; 29(6):3090-3099. PubMed ID: 30547205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gd-EOB-DTPA enhanced MRI of the liver: correlation of relative hepatic enhancement, relative renal enhancement, and liver to kidneys enhancement ratio with serum hepatic enzyme levels and eGFR.
    Talakic E; Steiner J; Kalmar P; Lutfi A; Quehenberger F; Reiter U; Fuchsjäger M; Schöllnast H
    Eur J Radiol; 2014 Apr; 83(4):607-11. PubMed ID: 24380639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.